Weaver Gregory L reported option exercise involving 18,750 shares of Altimmune, Inc. at $0.00 for $0 on Nov 11, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
18,750Common Stock, par value $0.0001
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
68,677Direct
Trade date
Nov 11, 2026Option exercise
Filed
Nov 13, 2026, 4:05 PM ET2-day reporting delay
Accession
0001251779-26-000015Code M · Transaction 400504
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Tax withholding5,672$1.93−$10,946.96Trade 400505
Nov 11, 2026Option exercise18,750$0.00$0Trade 400506
3 transaction rows in this filing. Joint filers share the same rows.

ALT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ALT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +25%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. F3: The RSUs become vested over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.